Victor M. Orellana‐Noia

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh et al. · Blood · 2021 · 122 citations · Full text

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Jeremy S. Abramson, Matthew Ku, Mark P. Hertzberg et al. · The Lancet · 2024 · 114 citations

Hematological Malignancy, Open-label Trial, Lymphoid Neoplasia +8

Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

Victor M. Orellana‐Noia, Daniel Reed, Ashley McCook et al. · Blood · 2021 · 91 citations · Full text

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens et al. · Blood Advances · 2021 · 51 citations · Full text

Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study

Adam Zayac, Andrew M. Evens, Alexey V. Danilov et al. · Haematologica · 2021 · 40 citations · Full text